Arcturus Therapeutics (ARCT) Set to Release Quarterly Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Arcturus Therapeutics to announce earnings of ($0.6804) per share and revenue of $8.00 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. On average, analysts expect Arcturus Therapeutics to post ($3.48) EPS for the current fiscal year and ($3.59) EPS for the next fiscal year.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $12.07 on Thursday. The stock’s 50 day moving average price is $13.57 and its 200 day moving average price is $8.95. Arcturus Therapeutics has a 52 week low of $5.50 and a 52 week high of $17.96. The company has a market capitalization of $343.07 million, a P/E ratio of -3.65 and a beta of 2.48.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ARCT. Wall Street Zen lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Zacks Research raised shares of Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Thursday, October 15th. Roth Capital reiterated a “buy” rating and set a $41.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd. Finally, Citigroup raised Arcturus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $8.00 to $20.00 in a report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.29.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.